Investment Rating - The report initiates coverage with an "Accumulate" investment rating for the company [1][3]. Core Views - The company is a rare platform-type entity in the A-share market, mastering the underlying technology of ultrasound and continuously advancing applications in various segments, including lithium batteries, semiconductor advanced packaging, and medical aesthetics. This platform capability provides resilience across economic cycles, with the second growth curve already beginning to materialize [1][7][14]. - The company is positioned to replicate its growth trajectory in the lithium battery sector within the advanced packaging equipment market, driven by strong domestic demand for localization [7][21]. Financial Data and Valuation - The company forecasts total revenue growth from 5.25 billion CNY in 2023 to 15.32 billion CNY in 2027, with year-on-year growth rates of 34% and 40% for 2025 and 2026 respectively [2][8]. - The net profit attributable to shareholders is expected to rise from 670 million CNY in 2023 to 3.81 billion CNY in 2027, with significant growth rates of 76% and 64% for 2025 and 2026 respectively [2][8]. - The company's price-to-earnings (PE) ratio is projected to decrease from 206.9 in 2023 to 36.2 by 2027, indicating improving valuation metrics as earnings grow [2][8]. Company Overview - The company has been a leader in the domestic ultrasound equipment market for nearly 20 years, with a comprehensive ultrasound technology platform that supports various industries, including lithium batteries, photovoltaic energy storage, semiconductors, automotive wiring, and medical aesthetics [7][34]. - The company has established a stable revenue stream from consumables, which accounted for 31.42% of total revenue in 2024, reflecting a strong business model that combines equipment sales with high-margin consumables [34][30]. Growth Curves - The first growth curve is driven by the recovery in capital expenditures in the lithium battery sector, with new technologies like solid-state batteries creating additional demand for equipment [18][21]. - The second growth curve focuses on advanced packaging equipment, where the company has secured orders and is positioned to lead in domestic market share [21][22]. - The third growth curve involves strategic expansion into the medical aesthetics sector, with significant market potential anticipated in the coming years [21][22]. Profitability and Financial Performance - The company has shown a compound annual growth rate (CAGR) of 32.32% in revenue from 2018 to 2024, with a notable recovery in profitability expected as market conditions improve [39][42]. - The gross margin for consumables is projected to reach 75.93% in 2024, significantly higher than the overall product margins, contributing to enhanced profitability [27][30]. - The company maintains a high research and development expenditure rate, which supports its long-term growth strategy and technological advancements [51].